Jang Ho Cho1, Sung Hee Lim2, Ho Jung An3, Ki Hwan Kim4, Keon Uk Park5, Eun Joo Kang6, Yoon Hee Choi7, Mi Sun Ahn8, Myung Hee Lee9, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Myung-Ju Ahn1. 1. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea. 3. St Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. 4. Boramae Medical Center, Seoul National University Hospital, Seoul, Republic of Korea. 5. Dongsan Hospital, Keimyung University, Daegu, Republic of Korea. 6. Guro Hospital, Korea University Medical Center, Seoul, Republic of Korea. 7. Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea. 8. Ajou University Medical Center, Suwon, Republic of Korea. 9. Samsung Medical Center, Seoul, Republic of Korea.
Abstract
PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed metastatic or recurrent NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R and T790M mutations, and exon 20 insertion were eligible for the study. The primary end point of objective response rate was assessed every 6 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary end points were progression-free survival, overall survival, duration of response, and safety. RESULTS: Between March 2016 and October 2017, 37 patients were enrolled. All were evaluable except one patient who withdrew consent after starting treatment. Median age was 60 years, and 22 (61%) were male. Among patients, 61% received osimertinib as first-line therapy. The mutations identified were G719X (n = 19; 53%), followed by L861Q (n = 9; 25%), S768I (n = 8; 22%), and others (n = 4; 11%). Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%). Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5 months), and median overall survival was not reached. Median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months). Adverse events of any grade were rash (n = 11; 31%), pruritus (n = 9; 25%), decreased appetite (n = 9; 25%), diarrhea (n = 8; 22%), and dyspnea (n = 8; 22%), but all adverse events were manageable. CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.
PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed metastatic or recurrent NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R and T790M mutations, and exon 20 insertion were eligible for the study. The primary end point of objective response rate was assessed every 6 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary end points were progression-free survival, overall survival, duration of response, and safety. RESULTS: Between March 2016 and October 2017, 37 patients were enrolled. All were evaluable except one patient who withdrew consent after starting treatment. Median age was 60 years, and 22 (61%) were male. Among patients, 61% received osimertinib as first-line therapy. The mutations identified were G719X (n = 19; 53%), followed by L861Q (n = 9; 25%), S768I (n = 8; 22%), and others (n = 4; 11%). Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%). Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5 months), and median overall survival was not reached. Median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months). Adverse events of any grade were rash (n = 11; 31%), pruritus (n = 9; 25%), decreased appetite (n = 9; 25%), diarrhea (n = 8; 22%), and dyspnea (n = 8; 22%), but all adverse events were manageable. CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.
Authors: Kartik Konduri; Jean-Nicolas Gallant; Young Kwang Chae; Francis J Giles; Barbara J Gitlitz; Kyle Gowen; Eiki Ichihara; Taofeek K Owonikoko; Vijay Peddareddigari; Suresh S Ramalingam; Satyanarayan K Reddy; Beth Eaby-Sandy; Tiziana Vavalà; Andrew Whiteley; Heidi Chen; Yingjun Yan; Jonathan H Sheehan; Jens Meiler; Deborah Morosini; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Christine M Lovly Journal: Cancer Discov Date: 2016-04-21 Impact factor: 39.397
Authors: Daniel G Coit; John A Thompson; Alain Algazi; Robert Andtbacka; Christopher K Bichakjian; William E Carson; Gregory A Daniels; Dominick DiMaio; Marc Ernstoff; Ryan C Fields; Martin D Fleming; Rene Gonzalez; Valerie Guild; Allan C Halpern; F Stephen Hodi; Richard W Joseph; Julie R Lange; Mary C Martini; Miguel A Materin; Anthony J Olszanski; Merrick I Ross; April K Salama; Joseph Skitzki; Jeff Sosman; Susan M Swetter; Kenneth K Tanabe; Javier F Torres-Roca; Vijay Trisal; Marshall M Urist; Nicole McMillian; Anita Engh Journal: J Natl Compr Canc Netw Date: 2016-04 Impact factor: 11.908
Authors: Y-L Wu; C Zhou; C-K Liam; G Wu; X Liu; Z Zhong; S Lu; Y Cheng; B Han; L Chen; C Huang; S Qin; Y Zhu; H Pan; H Liang; E Li; G Jiang; S H How; M C L Fernando; Y Zhang; F Xia; Y Zuo Journal: Ann Oncol Date: 2015-06-23 Impact factor: 32.976
Authors: M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel Journal: Ann Oncol Date: 2013-11-26 Impact factor: 32.976
Authors: Hiroki Sato; Michael Offin; Daisuke Kubota; Helena A Yu; Clare Wilhelm; Shinichi Toyooka; Romel Somwar; Mark G Kris; Marc Ladanyi Journal: J Thorac Oncol Date: 2020-10-07 Impact factor: 15.609